Squarepoint’s Telomir Pharmaceuticals TELO Stock Holding History

Squarepoint’s Portfolio TELO Stock Details TELO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,829	Closed	-$13.5K	–	5111
2025 Q2	$13.5K	Buy	+10,829	New	+$25K	﹤0.01%	4405

Other funds holding TELO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

SEM

Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Squarepoint's TELO Position: Q3 2025 in Review

Squarepoint sold out of Telomir Pharmaceuticals (TELO) in Q3 2025, closing a stake of 10,829 shares — an estimated $13.5K sold.

Squarepoint first reported a position in TELO in Q2 2025 and held it in 1 quarter. The position peaked at $13.5K in Q2 2025. 32 funds tracked by Wall St. Rank hold TELO as of Q3 2025.

Squarepoint reported no remaining Telomir Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Squarepoint sold 10,829 Telomir Pharmaceuticals shares in Q3 2025, an estimated $13.5K.
Squarepoint first reported a position in Telomir Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Squarepoint's Telomir Pharmaceuticals position peaked at $13.5K in Q2 2025.
32 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q3 2025.

Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.